Supernus Pharmaceuticals, Inc. (SUPN) · Nov 2, 2026 · Acquisition
$1B merger close — 1.5401 shares per Supernus share; $1.0B special dividend; $650M term loan
Supernus completes its merger with Indivior, creating a broader CNS drug company. The deal was expected, but closes with $650 million of new term debt.
Supernus was already a commercial CNS company building around nine U.S. products, including Qelbree, GOCOVRI, ZURZUVAE and newly launched ONAPGO; the announced Indivior combination was designed to create an approximately $2.2 billion-revenue, 11-product platform with expected annual cost synergies.
The transaction is now operational, not merely announced. Supernus confirms the merger has closed and the combined company has launched, with Supernus’ headquarters, Jack Khattar as CEO and an evenly split eight-member board. 〔0〕 This removes closing and approval risk, but the core terms were already disclosed and expected for the fourth quarter, so the announcement itself is largely confirmation rather than a fresh strategic surprise.
The main new economic reality is the balance-sheet burden funding Indivior holders’ cash payout. The combined company is using a $650 million term loan and existing cash to fund the $1.0 billion special dividend. That was also part of the announced structure, but it means the promised scale and synergy benefits must now be delivered while the new company carries additional debt and absorbs two operating organizations.
Control lands slightly more with legacy Indivior shareholders, despite the merger-of-equals framing. Former Indivior holders own approximately 56.5% and former Supernus holders 43.5% of the combined company. 〔1〕 That is consistent with the pre-announced exchange ratio and ownership split, so it changes governance in practice but not the market’s prior understanding of the deal.
| Deal terms | At close | Comparison |
|---|---|---|
| Exchange ratio (Merger terms) | 1.5401 shares | — |
| Special dividend (Merger terms) | $1.0B | — |
| Term loan (Financing terms) | $650M | — |
| Former Indivior ownership (Ownership) | 56.5% | — |
| Former Supernus ownership (Ownership) | 43.5% | — |
Bottom line: This is a meaningful business transition, but not a meaningful surprise: the planned CNS combination has closed on its announced terms. The upside case now depends on integration and synergies, while the immediate complication is the debt and cash used to fund the special dividend.
Combined-company first earnings report
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!